Prasithsirikul Wisit, Nopsopon Tanawin, Phutrakool Phanupong, Suwanwattana Pawita, Kantagowit Piyawat, Pongpirul Wannarat, Jongkaewwattana Anan, Pongpirul Krit
Bamrasnaradura Infectious Diseases Institute, Nonthaburi 11000, Thailand.
Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Vaccines (Basel). 2022 Jun 16;10(6):959. doi: 10.3390/vaccines10060959.
Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD with HD patients was limited. Moreover, the immunological response to COVID-19 infection was inconclusive in patients with ESRD and HD. The aim of this study was to investigate the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immunological response after COVID-19 infection in ESRD patients with HD. The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method, using Euroimmun. This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot ChAdOx1 nCoV-19-vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at 1 month after one-shot vaccination and slightly dropped to 58.73% at the 3-month follow-up, then was 92.06% at 1 month after two-shot vaccination and reduced to 82.26% at the 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at 1 month post-recovery and 92.50% at 3-month follow-up. This study demonstrated the immunogenicity of two-dose ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months.
接受血液透析（HD）的终末期肾病（ESRD）患者在接种mRNA新冠疫苗后免疫反应降低。ChAdOx1 nCoV-19是一种很有前景的新冠疫苗，在普通人群中表现良好，但关于其在接受HD的ESRD患者中的免疫原性证据有限。此外，ESRD合并HD患者对新冠病毒感染的免疫反应尚无定论。本研究旨在调查ChAdOx1 nCoV-19疫苗接种的免疫原性以及ESRD合并HD患者感染新冠病毒后的免疫反应。在每次注射或康复后的基线、1个月和3个月随访时采集血样。使用欧蒙公司的酶联免疫吸附测定（ELISA）法对所有参与者检测抗刺突蛋白IgG。本研究发现，两剂ChAdOx1 nCoV-19疫苗接种1个月后抗刺突蛋白IgG显著增加，随后3个月显著下降。另一方面，康复后组的抗刺突蛋白IgG保持稳定。单剂ChAdOx1 nCoV-19疫苗接种组和康复后组在1个月和3个月随访时抗刺突蛋白IgG的变化无显著差异。接种组单剂接种后1个月的血清转化率为60.32%，3个月随访时略有下降至58.73%，两剂接种后1个月为92.06%，3个月随访时降至82.26%。康复组康复后1个月的血清转化率为95.65%，3个月随访时为92.50%。本研究证明了两剂ChAdOx1 nCoV-19疫苗在ESRD合并HD患者中对体液免疫的免疫原性。新冠病毒感染后，体液免疫反应强烈且至少可维持三个月。
